BR112015014174A2 - composição de vacina para indivíduos virgens - Google Patents

composição de vacina para indivíduos virgens

Info

Publication number
BR112015014174A2
BR112015014174A2 BR112015014174A BR112015014174A BR112015014174A2 BR 112015014174 A2 BR112015014174 A2 BR 112015014174A2 BR 112015014174 A BR112015014174 A BR 112015014174A BR 112015014174 A BR112015014174 A BR 112015014174A BR 112015014174 A2 BR112015014174 A2 BR 112015014174A2
Authority
BR
Brazil
Prior art keywords
individuals
virgin
vaccine
vaccine composition
composition
Prior art date
Application number
BR112015014174A
Other languages
English (en)
Portuguese (pt)
Inventor
Maltais Anna-Karin
Arwidsson Hans
Original Assignee
Eurocine Vaccines Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eurocine Vaccines Ab filed Critical Eurocine Vaccines Ab
Publication of BR112015014174A2 publication Critical patent/BR112015014174A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/145—Orthomyxoviridae, e.g. influenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5252—Virus inactivated (killed)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/543—Mucosal route intranasal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55588—Adjuvants of undefined constitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Pulmonology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Otolaryngology (AREA)
  • Medicinal Preparation (AREA)
BR112015014174A 2012-12-17 2013-12-17 composição de vacina para indivíduos virgens BR112015014174A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP12197522.1A EP2742952A1 (en) 2012-12-17 2012-12-17 Influenza vaccine composition
PCT/EP2013/077006 WO2014095943A1 (en) 2012-12-17 2013-12-17 Vaccine composition for naive subjects

Publications (1)

Publication Number Publication Date
BR112015014174A2 true BR112015014174A2 (pt) 2017-07-11

Family

ID=47358019

Family Applications (2)

Application Number Title Priority Date Filing Date
BR112015014174A BR112015014174A2 (pt) 2012-12-17 2013-12-17 composição de vacina para indivíduos virgens
BR112015014243A BR112015014243A8 (pt) 2012-12-17 2013-12-17 composição de vacina para uso em populações imunocomprometidas e uso da mesma

Family Applications After (1)

Application Number Title Priority Date Filing Date
BR112015014243A BR112015014243A8 (pt) 2012-12-17 2013-12-17 composição de vacina para uso em populações imunocomprometidas e uso da mesma

Country Status (12)

Country Link
US (2) US20150306204A1 (OSRAM)
EP (4) EP2742952A1 (OSRAM)
JP (3) JP2016502997A (OSRAM)
KR (3) KR20210007042A (OSRAM)
CN (3) CN112826929A (OSRAM)
AU (2) AU2013360889C1 (OSRAM)
BR (2) BR112015014174A2 (OSRAM)
CA (2) CA2895028A1 (OSRAM)
HK (2) HK1212611A1 (OSRAM)
MX (2) MX2015007753A (OSRAM)
RU (2) RU2661408C2 (OSRAM)
WO (2) WO2014095943A1 (OSRAM)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103298484B (zh) * 2010-09-30 2017-04-26 优若森疫苗公司 改进的疫苗组合物
EP4144369A1 (en) * 2014-09-26 2023-03-08 Seqirus UK Limited Vaccination of immunocompromised subjects
JP2017528511A (ja) 2014-09-26 2017-09-28 セキラス ユーケー リミテッド 免疫低下された被験体のワクチン接種
RU2634247C2 (ru) * 2015-09-28 2017-10-24 Федеральное государственное бюджетное научное учреждение "СЕВЕРО-КАВКАЗСКИЙ ЗОНАЛЬНЫЙ НАУЧНО-ИССЛЕДОВАТЕЛЬСКИЙ ВЕТЕРИНАРНЫЙ ИНСТИТУТ" (ФГБНУ СКЗНИВИ) Способ стимуляции иммунного ответа и препарат для его осуществления
US20200306364A1 (en) * 2017-11-30 2020-10-01 Ohio State Innovation Foundation Mucoadhesive nanoparticle entrapped influenza virus vaccine delivery system
EP4135519B1 (en) * 2020-04-16 2024-09-25 Bayer Aktiengesellschaft Active compound combinations and fungicide compositions comprising those
US20230133087A1 (en) * 2020-04-16 2023-05-04 Bayer Aktiengesellschaft Active compound combinations and fungicide compositions comprising those
WO2021209364A1 (en) * 2020-04-16 2021-10-21 Bayer Aktiengesellschaft Active compound combinations and fungicide compositions comprising those
CN112063699B (zh) * 2020-09-16 2021-06-18 成都市疾病预防控制中心 一种用于研究hiv感染者免疫衰老机制的系统
WO2023133342A2 (en) * 2022-01-10 2023-07-13 The Children's Medical Center Corporation Methods and compositions relating to immunization of immune distinct patients

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9602280D0 (sv) 1996-06-10 1996-06-10 Pharmatrix Ab Immunstimulerande lipidformulering
SE9900496D0 (sv) 1999-02-12 1999-02-12 Pharmatrix Ab Vaccine formulation
US8410248B2 (en) 1999-03-12 2013-04-02 Human Genome Sciences Inc. HWBAO62 polypeptides
JP2004527524A (ja) 2001-04-05 2004-09-09 カイロン コーポレイション 非経口初回抗原刺激後の粘膜追加免疫
US20050208602A1 (en) 2001-08-10 2005-09-22 Rosen Craig A 89 human secreted proteins
WO2004042000A2 (en) 2002-05-17 2004-05-21 Human Genome Sciences, Inc. 157 human secreted proteins
DK1567191T3 (da) 2002-11-26 2011-01-03 Eurocine Vaccines Ab Ny amin-baseret adjuvans
CN1867355A (zh) 2003-08-11 2006-11-22 财团法人阪大微生物病研究会 包含诱导粘膜免疫的佐剂的新型疫苗
WO2006125076A2 (en) 2005-05-18 2006-11-23 Trinity Biosystems, Inc. Methods and compositions for immunizing against chlamydia infection
KR101294455B1 (ko) 2005-06-30 2013-08-07 에자이 알앤드디 매니지먼트 가부시키가이샤 면역 아쥬반트 제조용 화합물
US8211442B2 (en) 2005-08-05 2012-07-03 The University Of Tokushima Mucosal vaccine enabling switching from production of IgA antibody to production of both of IgA and IgG antibodies
RU2323742C1 (ru) * 2007-02-15 2008-05-10 Государственное учреждение Научно-исследовательский институт вакцин и сывороток им. И.И. Мечникова (ГУ НИИВС им. И.И. Мечникова) Способ повышения иммуногенности инактивированной гриппозной вакцины
EP2227251A1 (en) * 2007-12-06 2010-09-15 GlaxoSmithKline Biologicals SA Influenza composition
CA2725381A1 (en) 2008-05-23 2010-03-25 The Regents Of The University Of Michigan Nanoemulsion adjuvants
US9415006B2 (en) 2008-05-23 2016-08-16 The Regents Of The University Of Michigan Immunogenic compositions comprising nanoemulsion and hepatitis B virus immunogen and methods of using the same
US20130178383A1 (en) 2008-11-12 2013-07-11 David Spetzler Vesicle isolation methods
ES2618576T3 (es) 2009-05-28 2017-06-21 Curna, Inc. Tratamiento de enfermedades relacionadas con un gen antivírico mediante la inhibición de una transcripción antisentido natural a un gen antivírico
CN103298484B (zh) 2010-09-30 2017-04-26 优若森疫苗公司 改进的疫苗组合物

Also Published As

Publication number Publication date
EP3431101A1 (en) 2019-01-23
RU2015129028A (ru) 2017-01-23
CN112826929A (zh) 2021-05-25
AU2013360889B2 (en) 2016-12-01
AU2013360890A1 (en) 2015-07-02
JP2016502996A (ja) 2016-02-01
EP2742952A1 (en) 2014-06-18
CA2895023A1 (en) 2014-06-26
AU2013360890B2 (en) 2017-04-13
BR112015014243A2 (pt) 2017-07-11
AU2013360889C1 (en) 2017-06-08
KR20210007042A (ko) 2021-01-19
RU2661408C2 (ru) 2018-07-16
KR20150132093A (ko) 2015-11-25
CN104884085A (zh) 2015-09-02
MX2015007688A (es) 2015-09-07
WO2014095943A1 (en) 2014-06-26
MX2015007753A (es) 2016-01-08
JP2019112448A (ja) 2019-07-11
BR112015014243A8 (pt) 2019-10-08
JP2016502997A (ja) 2016-02-01
EP2931308A1 (en) 2015-10-21
RU2661407C2 (ru) 2018-07-16
EP2931307B1 (en) 2018-09-12
HK1213492A1 (zh) 2016-07-08
EP2931308B1 (en) 2018-10-10
RU2015129077A (ru) 2017-01-23
CN104870010A (zh) 2015-08-26
KR20150132092A (ko) 2015-11-25
AU2013360889A1 (en) 2015-07-02
HK1212611A1 (zh) 2016-06-17
EP2931307A1 (en) 2015-10-21
US20150306205A1 (en) 2015-10-29
WO2014095944A1 (en) 2014-06-26
US20150306204A1 (en) 2015-10-29
US11065325B2 (en) 2021-07-20
CA2895028A1 (en) 2014-06-26

Similar Documents

Publication Publication Date Title
BR112015014174A2 (pt) composição de vacina para indivíduos virgens
CY1122189T1 (el) Ιονικες υδατικες συνθεσεις
EA201590343A1 (ru) Алкилпиримидиновые производные для лечения вирусных инфекций и дальнейших заболеваний
BR112014024672A8 (pt) Composições farmacêuticas para terapia de combinação
CL2012001836A1 (es) Compuestos de pirazol, antagonista de crth2; composicion farmacéutica; uso en el tratamiento de trastornos inflamatorios, infecciosos, inmunoreguladores, enfermedades respiratorias, gastrointestinales o dolencias, entre otros.
EA028928B9 (ru) 2'-замещенные карбануклеозидные аналоги для противовирусного лечения
MX383706B (es) Composiciones de cenicriviroc y métodos para elaborarlas y usarlas.
BR112015003590A8 (pt) Métodos para tratamento ou prevenção da asma por administração de um antagonista de il-4r
BR112014026703A2 (pt) inibidores de dna-pk
BR112015007366A2 (pt) derivados de acilaminopirimidina para o tratamento de infecções virais e outras doenças
BR112015001313A2 (pt) composições de vacina
BR112014018953A8 (pt) Derivados de lupano triterpenoide e uso farmacêutico dos mesmos
BR102013003570A8 (pt) Composições de plasma rico em plaquetas
BR112012012862A2 (pt) composição farmacêutica compreendendo oligopeptídeos
BR112015017251A8 (pt) composições farmacêuticas compreendendo doadores de nitroxil, misturas e usos das referidas composições farmacêuticas
DOP2012000279A (es) Composiciones farmaceuticas que comprenden hidromorfona y naloxona
CO6640216A2 (es) Composiciones farmacéuticas que comprenden hidromorfona y naloxona
BRPI0915119B8 (pt) uso de iota carragenano
BR112012015202A2 (pt) "iota - e/ou kappa-carrgenado junto com um inibidor da neuraminidase, método para o tratamento profilático ou terapêutico de um sintoma, condição ou doença, composição farmacêutica,e, kit de partes".
BRPI0918806A2 (pt) composição compreendendo quitosana para administração ocular de vaninas em aves
CO6660486A2 (es) Composición tópica famacéutica o cosmética útil para el tratamiento de enfermedades o condiciones que cursan con un déficit de la maduración de la envoltura córnea
BR112017022755A2 (pt) formulações de glucopiranosil lipídeo a e alérgeno a amendoim para administração sublingual
BR112015018200A2 (pt) composição mastigável para administração oral e processo para preparar a mesma
MX347911B (es) Vacuna contra virus de diarrea viral de bovinos.
BR112015015250A2 (pt) derivados de pirrolidina, composições farmacêuticas e usos dos mesmos

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B06I Publication of requirement cancelled [chapter 6.9 patent gazette]

Free format text: ANULADA A PUBLICACAO CODIGO 6.6.1 NA RPI NO 2462 DE 13/03/2018 POR TER SIDO INDEVIDA.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B11B Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements